Philogen S.p.A. PHIL.MI Stock
Philogen S.p.A. Price Chart
Philogen S.p.A. PHIL.MI Financial and Trading Overview
Philogen S.p.A. stock price | 18.15 EUR |
Previous Close | 16.4 EUR |
Open | 16.2 EUR |
Bid | 16.25 EUR x N/A |
Ask | 16.35 EUR x N/A |
Day's Range | 16.15 - 16.4 EUR |
52 Week Range | 13 - 16.76 EUR |
Volume | 1.61K EUR |
Avg. Volume | 10.8K EUR |
Market Cap | 656M EUR |
Beta (5Y Monthly) | 0.113314 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.15 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 17 EUR |
PHIL.MI Valuation Measures
Enterprise Value | 405.93M EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 24.35051 |
Price/Book (mrq) | 4.820528 |
Enterprise Value/Revenue | 15.068 |
Enterprise Value/EBITDA | 234.238 |
Trading Information
Philogen S.p.A. Stock Price History
Beta (5Y Monthly) | 0.113314 |
52-Week Change | 13.10% |
S&P500 52-Week Change | 20.43% |
52 Week High | 16.76 EUR |
52 Week Low | 13 EUR |
50-Day Moving Average | 15.29 EUR |
200-Day Moving Average | 14.67 EUR |
PHIL.MI Share Statistics
Avg. Volume (3 month) | 10.8K EUR |
Avg. Daily Volume (10-Days) | 13.61K EUR |
Shares Outstanding | 40.37M |
Float | 10.68M |
Short Ratio | N/A |
% Held by Insiders | 61.40% |
% Held by Institutions | 5.32% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -19.95% |
Operating Margin (ttm) | -0.49% |
Gross Margin | 51.04% |
EBITDA Margin | 6.43% |
Management Effectiveness
Return on Assets (ttm) | -0.065% |
Return on Equity (ttm) | -5.29% |
Income Statement
Revenue (ttm) | 26.94M EUR |
Revenue Per Share (ttm) | 0.66 EUR |
Quarterly Revenue Growth (yoy) | 124.50% |
Gross Profit (ttm) | 13.75M EUR |
EBITDA | 1.73M EUR |
Net Income Avi to Common (ttm) | -5376000 EUR |
Diluted EPS (ttm) | -0.13 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 86.2M EUR |
Total Cash Per Share (mrq) | 2.97 EUR |
Total Debt (mrq) | 15.76M EUR |
Total Debt/Equity (mrq) | 16.1 EUR |
Current Ratio (mrq) | 9.176 |
Book Value Per Share (mrq) | 3.371 |
Cash Flow Statement
Operating Cash Flow (ttm) | -4939000 EUR |
Levered Free Cash Flow (ttm) | -8378250 EUR |
Profile of Philogen S.p.A.
Country | Italy |
State | SI |
City | Sovicille |
Address | Via Bellaria, 35 |
ZIP | 53018 |
Phone | 39 0577 17816 |
Website | https://www.philogen.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 157 |
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase I clinical trial for the treatment of chronic inflammation; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. Philogen S.p.A. was founded in 1996 and is based in Sovicille, Italy.
Q&A For Philogen S.p.A. Stock
What is a current PHIL.MI stock price?
Philogen S.p.A. PHIL.MI stock price today per share is 18.15 EUR.
How to purchase Philogen S.p.A. stock?
You can buy PHIL.MI shares on the Milan exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Philogen S.p.A.?
The stock symbol or ticker of Philogen S.p.A. is PHIL.MI.
Which industry does the Philogen S.p.A. company belong to?
The Philogen S.p.A. industry is Biotechnology.
How many shares does Philogen S.p.A. have in circulation?
The max supply of Philogen S.p.A. shares is 40.29M.
What is Philogen S.p.A. Price to Earnings Ratio (PE Ratio)?
Philogen S.p.A. PE Ratio is now.
What was Philogen S.p.A. earnings per share over the trailing 12 months (TTM)?
Philogen S.p.A. EPS is -0.15 EUR over the trailing 12 months.
Which sector does the Philogen S.p.A. company belong to?
The Philogen S.p.A. sector is Healthcare.